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Franco Nessi, MD, Turin, Italy
Despite the improvement in diagnostic and therapeutic strategies, the treatment of thoracoabdominal aneurysms is still
burdened with a high incidence of peri/postoperative morbidity and mortality. The multilayer ﬂow modulator is a new
and promising technique for the treatment of such disease; however, some limits are still evident. We report the case of
a 76-year-old woman affected by a symptomatic thoracoabdominal aneurysm treated with multiple Cardiatis multilayer
ﬂow modulators complicated by aortic arch rupture on the ﬁfth postoperative day, with subsequent patient death. (J Vasc
Surg 2014;60:1348-52.)We report the case of a 76-year-old female affected by
thoracoabdominal aneurysm (TAA) type II (Crawford’s
classiﬁcation). The patient’s history revealed mild arterial
hypertension, chronic obstructive pulmonary disease, and
moderate renal failure. In February 2011, the patient pre-
sented to our clinic; the computed tomography angiog-
raphy (CTA) scan showed a maximum diameter of the
descending aorta of 75 mm and a dilatation in abdomen
of 60 mm. Despite our indication to treat the descending
TAA, the patient refused any kind of surgical/hybrid
repair. Three months later, the patient was referred to us
for the sudden onset of interscapular pain. The CTA
revealed an increased dilatation of 6 to 7 mm in 3 months
at the proximal third of the TAA without images of dissec-
tion or imminent rupture (Fig 1). The patient, despite the
symptomatic aneurysm (persistent pain) and its rapid
growth, rejected again any surgical/hybrid repair; the
only treatment she would accept was an endovascular
approach. Branched and fenestrated endovascular options
were preventively excluded due to the amount of time
needed to obtain the devices, while the chimney technique
was excluded due to its inadequacy. After receiving
informed consent from the patient and the hospital ethical
committee and Italian Public Health Ministry authoriza-
tion, an endovascular procedure with multiple Cardiatisthe Vascular and Endovascular Surgery Unit, Mauriziano Umberto I
ospital.
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8multilayer ﬂow modulators (CMFMs; Crossmed, Isnes,
Belgium) was planned. The CMFM, by virtue of its
three-dimensional geometry, slows down and laminates
blood ﬂow inside the aneurysm sac with immediate pres-
sure reduction (reducing the risk of aneurysm rupture),
generating stasis and formation of an organized thrombus
(in few months), while improving laminar ﬂow in the
main artery and surrounding vital branches.1,2 The main
limit of the CMFM is determined by the fact that it cannot
be used in a ruptured aneurysm because it cannot stop
bleeding, not being a covered stent. The CTA images
were reconstructed on a three-dimensional workstation
(3Mensio Vascular, Bilthoven, Netherlands), and vessel
diameters and lengths were calculated. We planned to use
three CMFMs (three pieces of 35-150 mm), releasing
them into the descending aorta by telescopic deployment
from the aortic bifurcation to the origin of the left subcla-
vian artery with a 4-cm overlap and an oversize of 10% in
the proximal landing zone and of 30% in the distal landing
zone. The procedure was performed by vascular surgeons
in an operating room equipped with a C-arm brillance
(Eurocolumbus, Milan, Italy). The ﬂuoroscopic control
images after the deployment of the modules and the
ballooning maneuver showed stent shortening with loss
of both central overlapping regions (Fig 2). To obviate
this, a fourth CMFM (40-120 mm) was positioned and
ballooned. It was also decided to balloon the proximal
end point due to a ﬂuoroscopic image of infolding
(Fig 2). During the procedure, the stent retracted and dis-
located with the loss of proximal sealing. We ﬁnally
deployed a ﬁfth CMFM (40-150 mm), covering the whole
aortic arch and landing in the ascending aorta (Fig 2).
The ﬁrst 4 postoperative days were characterized by difﬁ-
culties on respiratory exchanges without any neurolog-
ical/visceral complication. On the 5th postoperative day,
the situation dramatically collapsed; the patient became
Fig 1. The computed tomography angiography (CTA) showed the maximum increased dilatation of 81 mm at
vertebral T4-T6 and a dilatation of infrarenal abdominal aortic aneurysm of 60 mm. The size of the aortic arch at the
common carotid artery was 32 mm, at the subclavian artery was 30 mm, and the length between the common carotid
artery and the subclavian artery was 15 mm. The distal sealing zone, at the abdominal aortic artery, had a diameter of
26.5 mm and a length of sealing zone of 40 mm.
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Fig 2. A, Fluoroscopic images of Cardiatis multilayer ﬂow modulator (CMFM) deployment. B, Modules and the
ballooning maneuver showed CMFMs shortening with loss of both central overlapping regions. C-D, A fourth CMFM
was positioned and ballooned. Presence of an image of infolding in the proximal end point. E-H, After the proximal
end point ballooning, the CMFM retracted and dislocated, so a ﬁfth CMFM was deployed, covering the whole aortic
arch and landing in the ascending aorta. I-K, Fluoroscopic images of ﬁnal control after CMFMs’ deployment.
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Fig 3. The autopsy images revealed the rupture of the aortic arch
in proximity of the descending tract.
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The autopsy revealed a 6-cm tear of the aortic arch wall
with a conspicuous left hemothorax (Fig 3) and pointed
out that the CMFMs’ overlapping zone was too rigid to
accommodate the degree of aortic arch angulation, leading
to rupture.
DISCUSSION
The treatment of a TAA represents a high-risk surgical
and endovascular procedure with a perioperative mortality
rate of up to 50% in emergency cases.3 In the last decade,
new technologies have expanded the applicability of endo-
vascular aneurysm treatment to cases with anatomical
adverse conditions and in patients with poor overall
medical status.4 Despite improvements, the complexity
and often necessary customization of the prosthesis limits
the use of this method in emergency situtations.4 Multi-
layer stents have been successfully used for the treatment
of visceral and popliteal aneurysms with a cumulative pri-
mary and secondary patency rate of 86.9% and 90.7% at
1 year.1,5,6 In 2009, the CE Mark approved the use of
CMFM for the treatment of aortic aneurysms (TAAs and
abdominal aortic aneurysms [AAAs]).6-11 Currently, few
data on the reliability of the method are available, but
short-term outcome of asymptomatic TAA and AAA repair
with CMFM are encouraging, with a survival rate after
1 year from intervention at 92.4%.9-11 However, it has
been demonstrated that various complications including
endoleaks, limb occlusion, and device failure can develop
during follow-up.10,12,13 Ruptured aneurysms are consid-
ered to be the main contraindication to the use of
CMFM since the thrombosis process of the aneurysmalsac could require some months.5,9,14 Our case differs
from others in the literature because, for the ﬁrst time,
multiple CMFMs have been used in a symptomatic TAA.
Considering the procedure failure and the patient’s death,
it is questionable if it was the case of treating the patient, if
the patient’s own choices (no surgery) inﬂuenced the
outcome, and if it was an aggressive treatment. There are
some reasons that led us to use multiple CMFMs: the
patient refused any surgical/hybrid treatment but end-
ovascular; the symptomatic TAA without rupture; the
impossibility of waiting for the customization of a fenes-
trated or branched device; and the fast aneurysm growth
(6-7 mm in 3 months that likely suggested a high risk of
short-/middle-term rupture). If the patient had accepted
a surgical approach, we would have chosen the hybrid
treatment by a carotid-subclavian bypass graft and thoracic
endovascular aneurysm repair (TEVAR) deploying from
the common carotid artery to the celiac artery (without
a perfect seal zone in the thrombus), with a complete
exclusion of thoracic aneurysm, and then a delay to
a second stage with the treatment of visceral/infrarenal
aortic aneurysm by fenestrated or hybrid treatment. There-
fore, due to these reasons, we decided to treat the TAA by
using three CMFMs, but we found some difﬁculties: low
compliance of the device to ﬁt the size of the vessel after
its deployment with stent shortening and loss of overlap-
ping in some tracts, stent stretching in other tracts and
consequent infolding; dislodgment after ballooning
maneuvers with consequent loss of overlapping regions
and distal end points; and low operator experience in the
treatment of TAAs with CMFM. For these reasons, we
were forced to use two more CMFMs. Even if the short
postoperative observation did not show any complications
related to cerebral, spinal, visceral, or renal ischemia, the
ﬁnal result was a failure due to aortic arch rupture with
subsequent patient death.CONCLUSIONS
In the literature, the CMFM is an arising and prom-
ising device for the treatment of asymptomatic TAAs and
AAAs. However, our experience points out that the use
of this device in symptomatic TAAs did not have good
results, leading to aneurysm rupture and patient death.
Moreover, the CMFM poses some technical aspects that
should be known and debated, including the remarkable
deformation in diameters and length after balloon stretch-
ing and the extreme rigidity of the system of multiple
CMFMs. The CMFM is not a conventional stent, and we
still need to understand when and how to use it. Much
more experience is needed to validate the effectiveness of
the CMFM in symptomatic TAAs.REFERENCES
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